GlassScriptPhysician profile
Bhoomi Mehrotra
NPI 1245390392
$540.88
in general payments reported to CMS, 2019-2025
16 companies · $168 in 2025
The $168 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17.28 · 2021: $140 · 2023: $22.42 · 2024: $194 · 2025: $168.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $384.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $383.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Menarini Silicon Biosystems, INC. | $72.01 | 2023-2024 | Cellsearch |
| Novartis Pharmaceuticals Corporation | $63.96 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $63.36 | 2021-2024 | |
| Springworks Therapeutics, INC. | $55.74 | 2024-2025 | Ogsiveo |
| Tempus Ai, INC | $45.11 | 2025 | Xt Cdx |
| Janssen Scientific Affairs, LLC | $44.83 | 2025 | Rybrevant |
| Dendreon Pharmaceuticals LLC | $30.33 | 2024 | Provenge |
| Janssen Biotech, INC. | $29.66 | 2021 | |
| Astellas Pharma US INC | $25.93 | 2024 | Xtandi |
| Pharmacyclics LLC, An Abbvie Company | $23.31 | 2021 | |
| Beone Medicines USA, INC. | $19.68 | 2025 | Brukinsa |
| Seagen INC. | $19.51 | 2021 | |
| Global Blood Therapeutics, INC. | $18.25 | 2021 | |
| Array Biopharma INC | $17.28 | 2019 | |
| Gilead Sciences, INC. | $11.92 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bhoomi Mehrotra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.